Related Experiment Video
Updated: Jul 2, 2026

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas
Published on: January 26, 2024
Persistent postpartum proteinuria, renal dysfunction, and future chronic kidney disease risk in women with
Kazumasa Sugiura1, Tomohito Okamoto1, Yukiko Kohmura-Kobayashi1
1Department of Obstetrics and Gynecology, School of Medicine, Aichi Medical University, Nagakute, Aichi, Japan.
Objectives:
Previous studies demonstrated that preeclampsia (PE) with proteinuria is associated with concurrent renal injury. However, it is unclear how renal damage that occurs during pregnancy changes after delivery. This study was conducted to assess postpartum renal impairment in women with PE and to examine its possible link to the subsequent development of chronic kidney disease (CKD).
Study Design:
We conducted a retrospective cohort study analyzing a group of women with PE and proteinuria (PE-UP (+)) (N = 30). Control data were obtained from normotensive participants at 35 weeks of gestation (N = 20) and 12 weeks postpartum (N = 15).
Main Outcome Measures:
Serum hyaluronan (glycocalyx injury), urinary podocalyxin (podocyte injury), urinary liver-type fatty acid-binding protein (L-FABP) and N-acetyl-β-D-glucosaminidase (NAG) (tubular injury) were measured at PE diagnosis and at 12 weeks postpartum.
Results:
Based on the urinary protein/creatinine ratio (UPCR) at 12 weeks postpartum, the PE-UP (+) group was stratified into the PE-UP improved group (UPCR <0.15 g/g Cr; N = 20) and PE-UP persistent group (UPCR ≥0.15 g/g Cr; N = 10). The urinary L-FABP and NAG levels in the PE-UP improved group were significantly lower than those in the PE-UP persistent group. In contrast, the levels of hyaluronan and podocalyxin remained significantly elevated in both PE subgroups compared to those in the postpartum controls.
Conclusions:
Postpartum women with PE and prolonged proteinuria exhibit residual tubular dysfunction. Women with PE in whom proteinuria has resolved may still have residual glomerular damage at 12 weeks postpartum. The clinical trial described in this paper was registered at the UMIN Clinical Trials Registry under registration number UMIN000058351. URL of registration: https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000066708.
Related Concept Videos
Nephrotic Syndrome I : Introduction
Chronic Kidney Disease I: Introduction
Diabetic Nephropathy
Chronic Kidney Disease III: Interprofessional Care
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Kidney Disease II: Clinical Manifestations